45 and older, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Largest Change From Baseline on Clinical Pain RatingPrimary· 8 hour study session
The study will measure whether blinded study medications change clinical pain ratings (0-100 pain rating scale). Higher score indicates worse outcome. Biggest difference from baseline over the entire session is reported.
Baseline
Group
Value
95% CI
Placebo + Placebo
24.19
± 23.63
Hydromorphone + Placebo
30.48
± 27.39
Dronabinol + Placebo
28.55
± 26.78
Hydromorphone + Dronabinol
26.38
± 25.86
Peak Effect
Group
Value
95% CI
Placebo + Placebo
12.76
± 17.81
Hydromorphone + Placebo
9.40
± 16.27
Dronabinol + Placebo
12.80
± 17.50
Hydromorphone + Dronabinol
12.41
± 16.92
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 40 hours.
Reporting threshold: 1%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This research is being done to evaluate whether combining medications that are FDA approved, but have not yet been approved for combination treatment, can be effective in reducing pain.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03098563.